Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
COL6A2 CRISPR/Cas9 KO Plasmid (h): sc-403209
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- COL6A2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the COL6A2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: COL6A2 Antibody (B-7): sc-374566
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
COL6A2 CRISPR/Cas9 KO Plasmid (h) | sc-403209 | 20 µg | $397.00 |
Overview
COL6A2 encodes the α2 chain of collagen VI, an extracellular matrix (ECM) microfibrillar component that assembles with COL6A1 and COL6A3 to form beaded filaments in connective tissues. Collagen VI contributes to ECM organization, cell–matrix adhesion, and mechanotransduction, influencing cytoskeletal architecture and signaling pathways such as integrin/FAK, MAPK, and TGF-β–associated remodeling programs. Through these processes, COL6A2 helps regulate tissue integrity and cellular stress responses in fibroblasts, myocytes, and other stromal cell types. Pathogenic disruption of collagen VI assembly is linked to inherited neuromuscular and connective tissue disorders, making COL6A2 a relevant target for modeling ECM-driven phenotypes.
COL6A2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the COL6A2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the COL6A2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the COL6A2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish COL6A2 protein expression.
This CRISPR knockout system enables efficient generation of COL6A2-deficient cell models for investigation of COL6A2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting COL6A2 exon(s) critical for COL6A2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple COL6A2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by COL6A2 CRISPR/Cas9 KO Plasmid (h) and COL6A2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the COL6A2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by COL6A2 HDR Plasmid (h) and COL6A2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by COL6A2 homology arms to support homology-directed repair at defined COL6A2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.